Zymeworks adds a new lab for fast-growing R&D work; Novartis considers a spinoff for Alcon

  • Fast-growing Zymeworks has added a new, 10,000-square-foot lab in Vancouver to accomodate its research staff. “Zymeworks’ new lab is an investment in our future. It will enable us to perform our own internal research and development in a fully integrated manner,” said CEO Ali Tehrani. “As the Zymeworks family continues to grow, so do our requirements, and the capabilities our new lab provides demonstrate our commitment to efficiently advance and expand our therapeutic pipeline.”
  • As Novartis was bullishly upping its forecast on CAR-T, execs were being forced to explain some weak financials for 2016. The company is now mulling a possible spinoff of a struggling Alcon, reports the Financial Times. And it’s setting up a $5 billion buy back to help placate investors as it tries to wrestle out of its predicament.
  • Ann Arbor, MI-based Esperion Therapeutics $ESPR has completed enrollment in their pivotal Phase III long-term safety and tolerability study of bempedoic acid.
  • The FDA has OK’d Adapt Pharma’s Narcan Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->